返回
刘真真 (Zhenzhen Liu)
Henan University
43H指数
474论文数
6.7K被引数
收录论文 178
发表时间
Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase 3 trial新辅助曲妥珠单抗德鲁替康单药或序贯多西他赛、曲妥珠单抗和帕妥珠单抗治疗高危HER2阳性早期乳腺癌(DESTINY-Breast11):一项随机、开放标签、多中心、III期临床试验
Annals of Oncology
IF65.4

